Radioprotectors in treatment therapy to reduce risk in secondary tumor induction
- 31 December 1988
- journal article
- review article
- Published by Elsevier BV in Pharmacology & Therapeutics
- Vol. 39 (1-3), 21-25
- https://doi.org/10.1016/0163-7258(88)90035-6
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- The effect of 2-[(aminopropyl)amino] ethanethiol (WR1065) on radiation-induced DNA damage and repair and cell progression in V79 cellsBritish Journal of Cancer, 1986
- Protective effects of 2-[(aminopropyl)amino] ethanethiol against bleomycin and nitrogen mustard-induced mutagenicity in V79 cellsInternational Journal of Radiation Oncology*Biology*Physics, 1986
- SHORT COMMUNICATIONCarcinogenesis: Integrative Cancer Research, 1986
- Second cancers following antineoplastic therapyCurrent Problems in Cancer, 1985
- The radioprotector WR1065 reduces radiation-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in V79 cellsCarcinogenesis: Integrative Cancer Research, 1985
- Increased incidence of acute nonlymphocytic leukemia following therapy in patients with small cell carcinoma of the lung.Journal of Clinical Oncology, 1984
- Non-Hodgkin's lymphoma occurring after hodgkin's disease four new cases and a review of the literatureCancer, 1984
- Acute myelogenous leukemia as a second malignant neoplasm following the successful treatment of advanced Hodgkin's diseaseCancer, 1983
- Second neoplasms following radiotherapy or chemotherapy for cancerAmerican Journal of Clinical Oncology, 1982
- Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant diseaseBlood, 1981